These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 22465970

  • 1. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
    Zhu Y, Tang RK, Zhao P, Zhu SS, Li YG, Li JB.
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2016 Apr 21; 4(4):CD000543. PubMed ID: 27101467
    [Abstract] [Full Text] [Related]

  • 6. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000544. PubMed ID: 23076890
    [Abstract] [Full Text] [Related]

  • 7. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P.
    Am J Gastroenterol; 2012 Jul 17; 107(7):1064-77. PubMed ID: 22565161
    [Abstract] [Full Text] [Related]

  • 8. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE.
    Gastroenterology; 2007 Jan 17; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [Abstract] [Full Text] [Related]

  • 9. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Wang Y, Parker CE, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2016 May 09; 2016(5):CD000544. PubMed ID: 27158764
    [Abstract] [Full Text] [Related]

  • 10. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2020 Aug 28; 8(8):CD000544. PubMed ID: 32856298
    [Abstract] [Full Text] [Related]

  • 11. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
    Li W, Zhang ZM, Jiang XL.
    Colorectal Dis; 2016 Jul 28; 18(7):O214-23. PubMed ID: 27214762
    [Abstract] [Full Text] [Related]

  • 12. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.
    Tong JL, Huang ML, Xu XT, Qiao YQ, Ran ZH.
    J Dig Dis; 2012 Apr 28; 13(4):200-7. PubMed ID: 22435504
    [Abstract] [Full Text] [Related]

  • 13. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan 28; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 14. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2020 Aug 12; 8(8):CD000543. PubMed ID: 32786164
    [Abstract] [Full Text] [Related]

  • 15. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
    Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R.
    Gut; 2008 Jul 12; 57(7):893-902. PubMed ID: 18272546
    [Abstract] [Full Text] [Related]

  • 16. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
    Osterman MT, Lichtenstein GR.
    Methods Find Exp Clin Pharmacol; 2009 Jul 12; 31(1):41-6. PubMed ID: 19357797
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
    Zheng X, Zhang Z, Wang B, Li J, Qiu C, Zhang Q, Wang X.
    Medicine (Baltimore); 2019 Apr 12; 98(14):e15113. PubMed ID: 30946380
    [Abstract] [Full Text] [Related]

  • 18. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov 12; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
    Safdi AV, Cohen RD.
    Aliment Pharmacol Ther; 2007 Nov 01; 26(9):1179-86. PubMed ID: 17944732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.